• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ATALUREN Drug Record

  • Summary
  • Interactions
  • Claims
  • ATALUREN chembl:CHEMBL256997 Approved

    Alternate Names:

    ATALUREN
    PTC124
    PTC-124
    3-[5-(2-FLUOROPHENYL)-1,2,4-OXADIAZOL-3-YL]BENZOIC ACID
    EC-000.2051
    pubchem.compound:11219835
    chembl:CHEMBL256997
    drugbank:05016
    chemidplus:775304-57-9

    Drug Info:

    (0 More Sources)

    Publications:

    Shoseyov D et al., 2016, Ataluren for the treatment of cystic fibrosis., Expert Rev Respir Med
    Wilschanski M et al., 2011, Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis., Eur Respir J
    Sermet-Gaudelus I et al., 2010, Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis., Am J Respir Crit Care Med
    Kerem E et al., 2008, Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial., Lancet
  • ATALUREN   DMD

    Interaction Score: 6.87

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • ATALUREN   CFTR

    Interaction Score: 6.44

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26840186 21233271 20622033 18722008


    Sources:
    PharmGKB

  • ATALUREN   AR

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PharmGKB: ataluren

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Kerem E et al., 2008, Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial., Lancet
    Wilschanski M et al., 2011, Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis., Eur Respir J
    Shoseyov D et al., 2016, Ataluren for the treatment of cystic fibrosis., Expert Rev Respir Med

  • TTD: Ataluren

    • Version: 2020.06.01

    Alternate Names:
    D09IRQ TTD Drug ID

    Drug Info:

    Publications:

  • DTC: ATALUREN

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL256997 ChEMBL Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL256997

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21